Cellectricon

Executive Summary

Cellectricon is a Sweden-based contract research organization (CRO) specializing in neuroscience drug discovery. Founded in 2005, the company offers customized in vitro services including target discovery, lead optimization, and neurotoxicity testing for pharmaceutical and biotech clients. By leveraging innovative biological models and collaborative partnerships, Cellectricon aims to accelerate and de-risk early-stage neuroscience drug development. With a focus on high-quality, tailored research solutions, the company occupies a niche in the preclinical CRO market, serving clients seeking expertise in complex central nervous system (CNS) assays. Despite limited public information, Cellectricon's long-standing presence and specialized focus position it as a potential partner for CNS drug developers.

Upcoming Catalysts (preview)

• Q2 2026Announcement of major pharmaceutical partnership for CNS drug development services40% success
• Q4 2026Expansion of service offerings to include new neuroscience models (e.g., organoids or microphysiological systems)30% success
• Q1 2027Strategic collaboration or acquisition by larger CRO to expand geographic reach20% success